Systemic treatment

Best Practice and Research: Clinical Gastroenterology

Volumn 28, Issue 5, 2014, Pages 921-935

  Reig, Maria ^a,b   Gazzola, Alessia ^a   Di Donato, Roberto ^a   Bruix, Jordi ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Hepatocellular carcinoma; Management; Patients selection; RECIST; Systemic treatment; Tumour response

Indexed keywords

ANTINEOPLASTIC AGENT; BRIVANIB; CABOZANTINIB; CRIZOTINIB; DOXORUBICIN; EVEROLIMUS; LENVATINIB; LINIFANIB; RAMUCIRUMAB; SORAFENIB; SUNITINIB; TIVANTINIB; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ASTHENIA; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CHILD PUGH SCORE; CLINICAL PRACTICE; COMORBIDITY; CONSTIPATION; DIARRHEA; DRUG ERUPTION; DRUG TREATMENT FAILURE; ERYTHEMA; EVALUATION STUDY; FOLLICULITIS; HUMAN; HYPERTENSION; ISCHEMIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; PANCREATITIS; PERIPHERAL VASCULAR DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEINURIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SYSTEMIC THERAPY; TREATMENT RESPONSE; TUMOR VOLUME; VOICE CHANGE; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; PATIENT SELECTION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; NIACINAMIDE; PATIENT SELECTION; PHENYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 84921728501     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2014.08.003     Document Type: Review

References (59)

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012 Mar 31; 379 (9822) : 1245-55.
2. Reig M, Darnell A, Forner A, Rimola J, Ayuso C, Bruix J. Systemic therapy for hepatocellular carcinoma. The issue of treatment stage migration and registration of progression using the BCLC refined RECIST. Semin Liver Dis. 2015.
3. Croswell JM, Kramer BS. Clinical trial design and evidence-based outcomes in the study of liver diseases. J Hepatol 2009 Apr; 50 (4) : 817-26.
4. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology 2011 Mar; 53 (3) : 1020-2.
5. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 2002 May 18; 359 (9319) : 1734-9.
6. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002 May; 35 (5) : 1164-71.
7. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003 Feb; 37 (2) : 429-42.
8. de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. J Hepatol 2012; 56 (Suppl. 1) : S75-87.
9. Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol 2013 Oct 1; 31 (28) : 3501-8.
10. Castells A, Bruix J, Bru C, Ayuso C, Roca M, Boix L, et al. Treatment of hepatocellular carcinoma with tamoxifen: A doubleblind placebo-controlled trial in 120 patients. Gastroenterology 1995 Sep; 109 (3) : 917-22.
11. Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen. Hepatology 2004 Dec; 40 (6) : 1361-9.
12. Beaugrand M, Sala M, Degos F. Treatment of advanced hepatocellular carcinoma by seocalcitol (a vit D analogue) : An international randomized double-blind placebo-controlled study in 747 patients. J Hepatol 2005; 42 (Suppl. 2) : 17A.
13. Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000 Jan; 31 (1) : 54-8.
14. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008 Jul 24; 359 (4) : 378-90.
15. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009 Jan; 10 (1) : 25-34.
16. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004 Oct 1; 64 (19) : 7099-109.
17. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006 Sep 10; 24 (26) : 4293-300.
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000 Feb 2; 92 (3) : 205-16.
19. Raoul JL, Bruix J, Greten TF, Sherman M, Mazzaferro V, Hilgard P, et al. Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. J Hepatol 2012 May; 56 (5) : 1080-8.
20. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. J Hepatol 2012 Oct; 57 (4) : 821-9.
21. Llovet JM, Pena CE, Lathia CD, Shan M, Meinhardt G, Bruix J. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012 Apr 15; 18 (8) : 2290-300.
22. EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol 2012 Apr; 56 (4) : 908-43.
23. Verslype C, Rosmorduc O, Rougier P. Hepatocellular carcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012 Oct; 23 (Suppl. 7) : Vii41-8.
24. Reig M, Torres F, Rodriguez-Lope C, Forner A, LLarch N, Rimola J, et al. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. pii: S0168-8278 (14) 00211-6 J Hepatol 2014 Apr 2. http://dx.doi.org/10. 1016/j.jhep.2014.03.030 [Epub ahead of print].
25. Marrero J, Lencioni Riccardo, Ye Sheng-Long, Kudo Masatoshi, Bronowicki Jean-Pierre, Xiao-Ping Chen, et al. Final analysis of GIDEON (Global investigation of therapeutic decisions in hepatocellular carcinoma [HCC] and of its treatment with sorafenib [Sor]) in >3000 Sor-treated patients (pts) : Clinical findings in pts with liver dysfunction. J Clin Oncol 2013; 31 (Suppl.) . abstr 4126.
26. Di Costanzo GG, Tortora R, Iodice L, Lanza AG, Lampasi F, Tartaglione MT, et al. Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice. Dig Liver Dis 2012 Sep; 44 (9) : 788-92.
27. Nakazawa T, Hidaka H, Takada J, Okuwaki Y, Tanaka Y, Watanabe M, et al. Early increase in alpha-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol 2013 Jun; 25 (6) : 683-9.
28. Reig M, Rimola J, Torres F, Darnell A, Rodriguez-Lope C, Forner A, et al. Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design. Hepatology 2013 Dec; 58 (6) : 2023-31.
29. Organization WH. WHO handbook for reporting results of cancer treatment. Geneva Switzerland: World Health Organization; 1979 (Offset Publication 48) .
30. Moertel CG, Hanley JA. The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer 1976 Jul; 38 (1) : 388-94.
31. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) . Eur J Cancer 2009 Jan; 45 (2) : 228-47.
32. Bruix J, Reig M, Rimola J, Forner A, Burrel M, Vilana R, et al. Clinical decision making and research in hepatocellular carcinoma: Pivotal role of imaging techniques. Hepatology 2011 Dec; 54 (6) : 2238-44.
33. Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol 2012 Jun; 56 (6) : 1330-5.
34. Reig M, Matilla A, Bustamante J, Castells L, de La Mata M, Delgado M, et al. Recommendations for the management of sorafenib in patients with hepatocellular carcinoma. Gastroenterol Hepatol 2010 Dec; 33 (10) : 741-52.
35. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973 Aug; 60 (8) : 646-9.
36. Martin P, DiMartini A, Feng S, Brown Jr. R, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology 2014 Mar; 59 (3) : 1144-65.
37. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000 Apr; 31 (4) : 864-71.
38. Ma C, Bandukwala S, Burman D, Bryson J, Seccareccia D, Banerjee S, et al. Interconversion of three measures of performance status: An empirical analysis. Eur J Cancer 2010 Dec; 46 (18) : 3175-83.
39. European Medicines Agency. Sorafenib (Nexavar) : Summary of product characteristics [online]. URL; 2013., http://wwwemeaeuropaeu/humandocs/PDFs/EPAR/nexavar/H-690-PI-enpdf.
40. Finn RS. Drug therapy: Sorafenib. Hepatology 2010 May; 51 (5) : 1843-9.
41. Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, Villa E, et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy. Hepatology 2011 Dec; 54 (6) : 2055-63.
42. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography inpatients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. J Clin Oncol 2007 May 1; 25 (13) : 1753-9.
43. Kudo M, Kubo S, Takayasu K, Sakamoto M, Tanaka M, Ikai I, et al. Response evaluation criteria in cancer of the liver (RECICL) proposed by the liver cancer study group of Japan (2009 revised version) . Hepatol Res 2010 Jul; 40 (7) : 686-92.
44. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010 Feb; 30 (1) : 52-60.
45. Finn RS, Poon RT, Yau T, Klumpen HJ, Chen LT, Kang YK, et al. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. J Hepatol 2013 Dec; 59 (6) : 1271-7.
46. Koeberle D, Dufour J-F, Demeter G, Samaras P, Saletti P, Li Q, et al. Sorafenib with or without everolimus in patients with unresectable hepatocellular carcinoma (HCC) : A randomized multicenter phase II trial (SAKK 77/08 and SASL 29) . J Clin Oncol 2014; 32 (5s) . Suppl. abstr 4099.
47. Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial. J Clin Oncol 2013 Nov 10; 31 (32) : 4067-75.
48. Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study. J Clin Oncol 2013 Oct 1; 31 (28) : 3517-24.
49. Cainap C, Qin S, Huang W-T, Chung I-J, Pan H, Cheng Y, et al. Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC) . J Clin Oncol 2013; 31. Gastrointestinal Cancers Symposium (January 24-26, 2013) .No 4-suppl (February 1 Supplement) , 249) : (suppl 4; abstr 249.
50. Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: Results from the randomized phase III BRISK-PS study. J Clin Oncol 2013 Oct 1; 31 (28) : 3509-16.
51. Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib. The EVOLVE-1 randomized clinical trial. JAMA 2014; 312 (1) : 57-67.
52. REACH. Lilly announces top-line results of phase III REACH trial of CYRAMZA™ (ramucirumab) in patients with hepatocellular carcinoma; 2014. https://investorlillycom/releasedetailcfm?releaseid=854049.
53. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. A phase 3, multicenter, double-blind, placebocontrolled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT) . J Clin Oncol 2014; 32 (5s) . Suppl. abstr LBA6008.
54. Refametinib in RAS Mutant hepatocellular carcinoma (HCC) . http://clinicaltrialsgov/ct2/show/NCT01915589? term=ras+mutation%2C+hepatocellular+carcinoma& rank=1.
55. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013 Jun 20; 368 (25) : 2385-94.
56. Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013 Mar; 19 (3) : 329-36.
57. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: Immunoselection and immunosubversion. Nat Rev Immunol 2006 Oct; 6 (10) : 715-27.
58. Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer - what clinicians need to know. Nat Rev Clin Oncol 2011 Oct; 8 (10) : 577-85.
59. Yeo W, Chung HC, Chan SL, Wang LZ, Lim R, Picus J, et al. Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: A multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. J Clin Oncol 2012 Sep 20; 30 (27) : 3361-7.